Compare Equinor ASA (EQNR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Medpace Holdings Inc — how do they compare? Equinor ASA trades at $43.43 (market cap $101.62B), while Medpace Holdings Inc trades at $617.27 (market cap $16.82B). The key difference: Equinor ASA is far larger — about 6× Medpace Holdings Inc's market cap, and Equinor ASA pays a 3.63% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Medpace Holdings Inc for 14 Days on average.
| EQNR | MEDP | |
|---|---|---|
Market Cap | $101.62B | $16.82B |
Volume | 4,991,782 | 223,093 |
Sector | Energy | Health |
52-Week High | $45.75 | $630.19 |
52-Week Low | $22.41 | $393.42 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | $110.31B | $16.44B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $43.415, up 4.34% with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 11.63 and EV/EBITDA of 2.39, while maintaining solid profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues shareholder returns through dividends and buybacks.
EQNR presents compelling value with significant upside to the $87.50 consensus price target, though investors face risks from volatile energy prices and declining profit margins. The company's LNG expansion strategy and strong cash flow generation support long-term growth potential, while technical indicators suggest near-term bullish momentum may continue.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
